AllPennyStocks.com RVMD Stock Stays Flat Despite FDA Nod For $39,800-A-Month Pancreatic Cancer Pill — Is Drug Price Overshadowing Approval?
This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

RVMD Stock Stays Flat Despite FDA Nod For $39,800-A-Month Pancreatic Cancer Pill — Is Drug Price Overshadowing Approval?

The Food and Drug Administration (FDA) cleared the once-daily tablet, Rasonque, for certain adults with metastatic pancreatic adenocarcinoma.

Other Penny Stock Movers

$500 Million AI Merger Sends This Microcap Soaring
Historic Gold Ground Gets a Fresh Drill Test
Washington Is Financing Critical-Mineral Projects. What Will Canada Do?
Most Popular
{{ index + 1 }}


Back to Top